SPY765.45QQQ737.55+0.14%BTC/USD83,824.26+0.44%DIA513.34−0.13%GLD379.61+0.45%TLT78.72+0.13%
Benzinga

Assembly Biosciences Inc

ASMBNASDAQ
Trade with Public
Trade with Public
$23.61
-0.06-0.25%
At close: Sep 25, 5:00 PM EST
$23.61
-0.06-0.25%
Pre-Market: 4:09 AM EST
OverviewNewsEarnings ForecastEventsPrice TargetsFinancialsSentimentOwnershipCompareOptionsStock Report

Assembly Biosciences Analyst Price Targets

Wall Street analyst price targets and consensus rating for Assembly Biosciences (ASMB).

Price Target Range — 7 Quarters

Analyst Consensus — 6 Analysts

1S.Buy
5Buy
Consensus RatingBuy# Analysts6Avg. Consensus PT$45Upside to Avg. PT+89.4%

Rating Trend — Last 9 Months

Recent Analyst Actions

See all ratings →
DateFirmAnalystActionRating ChangePrice Target
Sep 1, 2026MizuhoSalim SyedPT CutOutperform$53→$45
Sep 1, 2026UBSAshwani VermaInitiateBuy$52
More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
Mizuho Maintains Outperform on Assembly Biosciences, Lowers Price Target to $45

Mizuho analyst Salim Syed maintains Assembly Biosciences (NASDAQ:ASMB) with a Outperform and lowers the price target from $53 to $45.
Benzinga Newsdesk

PRO
HC Wainwright & Co. Reiterates Buy on Assembly Biosciences, Maintains $50 Price Target

HC Wainwright & Co. analyst Patrick R. Trucchio reiterates Assembly Biosciences (NASDAQ:ASMB) with a Buy and maintains $50 price target.
Benzinga Newsdesk

PRO
Mizuho Maintains Outperform on Assembly Biosciences, Raises Price Target to $45

Mizuho analyst Salim Syed maintains Assembly Biosciences (NASDAQ:ASMB) with a Outperform and raises the price target from $40 to $45.
Benzinga Newsdesk

PRO
Guggenheim Reiterates Buy on Assembly Biosciences, Maintains $43 Price Target

Guggenheim analyst Vamil Divan reiterates Assembly Biosciences (NASDAQ:ASMB) with a Buy and maintains $43 price target.
Benzinga Newsdesk

PRO
HC Wainwright & Co. Reiterates Buy on Assembly Biosciences, Maintains $50 Price Target

HC Wainwright & Co. analyst Patrick R. Trucchio reiterates Assembly Biosciences (NASDAQ:ASMB) with a Buy and maintains $50 price target.
Benzinga Newsdesk

PRO
Guggenheim Maintains Buy on Assembly Biosciences, Raises Price Target to $43

Guggenheim analyst Vamil Divan maintains Assembly Biosciences (NASDAQ:ASMB) with a Buy and raises the price target from $39 to $43.
Benzinga Newsdesk

Data & APIs: Benzinga APIs · Stock News API · Analyst Ratings API · Company Logo API

Market data provided by Benzinga APIs

Connect With Us
instagramlinkedinyoutubeblueskymastodon
About Benzinga
Market Resources
Trading Tools & Education
Ring the Bell
© 2026 Benzinga | All Rights Reserved